Evidence map›Paper›PMID 33903232›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2021

Acquisition of optimal TFH cell function is defined by specific molecular, positional, and TCR dynamic signatures.

Kartika Padhan, Eirini Moysi, Alessandra Noto, Alexander Chassiakos, Khader Ghneim, Maria Maddalena Perra, Sanjana Shah, Vasilis Papaioannou, Giulia Fabozzi, David R Ambrozak and 9 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Trial
  2. Article
  3. Multimodal analysis definesbioRxiv : the preprint server for biology · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Frontiers in immunology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Kartika PadhanTissue Analysis Core, Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20814.ORCID 0000-0001-9561-4256
Eirini MoysiTissue Analysis Core, Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20814.
Alessandra NotoService of Immunology and Allergy, Department of Medicine, Lausanne University Hospital, University of Lausanne, 1011 Lausanne, Switzerland.ORCID 0000-0003-2813-9488
Alexander ChassiakosTissue Analysis Core, Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20814.
Khader GhneimDepartment of Pathology, Case Western Reserve University, Cleveland, OH 44106.
Maria Maddalena PerraService of Immunology and Allergy, Department of Medicine, Lausanne University Hospital, University of Lausanne, 1011 Lausanne, Switzerland.ORCID 0000-0002-0497-8511
Sanjana ShahHuman Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20814.
Vasilis PapaioannouTissue Analysis Core, Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20814.
Giulia FabozziTissue Analysis Core, Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20814.
David R AmbrozakImmunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20814.
Antigoni PoultsidiMedical School, University of Thessaly, Larissa 41222, Greece.ORCID 0000-0001-8804-729X
Maria IoannouMedical School, University of Thessaly, Larissa 41222, Greece.ORCID 0000-0003-2154-9310
Craig FenwickService of Immunology and Allergy, Department of Medicine, Lausanne University Hospital, University of Lausanne, 1011 Lausanne, Switzerland.
Samuel DarkoHuman Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20814.ORCID 0000-0002-9711-8122
Daniel C DouekHuman Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20814.
Rafick-Pierre SekalyDepartment of Pathology, Case Western Reserve University, Cleveland, OH 44106.
Giuseppe PantaleoService of Immunology and Allergy, Department of Medicine, Lausanne University Hospital, University of Lausanne, 1011 Lausanne, Switzerland.
Richard A KoupImmunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20814.ORCID 0000-0002-3090-7282
Constantinos PetrovasTissue Analysis Core, Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20814; petrovasc@mail.nih.gov.

Funding

Tfh and B cells in HIV/SIV pathogenesis and vaccinationZIAAI005015 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI KOUP, RICHARD A · 2009 to 2025
$24.1M
Host Genomic Factors in Infectious Disease Susceptibility ZIAAI005066 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DOUEK, DANIEL CESAR · 2009 to 2025
$17.9M
The Genome Analysis CoreZICAI005133 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DOUEK, DANIEL CESAR · 2019 to 2025
$16.9M
T Cell Immune Responses To HIV And Other PathogensZIAAI005033 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DOUEK, DANIEL CESAR · 2009 to 2025
$11.4M
The HIV ReservoirZIAAI005034 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DOUEK, DANIEL CESAR · 2009 to 2025
$7.5M
Innate and Adaptive Immune Responses in SARS-CoV-2 infection (COVID-19)ZIAAI005151 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DOUEK, DANIEL CESAR · 2020 to 2025
$6.8M
InflammationZIAAI005031 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DOUEK, DANIEL CESAR · 2009 to 2024
$5.9M
6 · The paper itself

Abstract

The development of follicular helper CD4 T (TFH) cells is a dynamic process resulting in a heterogenous pool of TFH subsets. However, the cellular and molecular determinants of this heterogeneity and the possible mechanistic links between them is not clear. We found that human TFH differentiation is associated with significant changes in phenotypic, chemokine, functional, metabolic and transcriptional profile. Furthermore, this differentiation was associated with distinct positioning to follicular proliferating B cells. Single-cell T cell receptor (TCR) clonotype analysis indicated the transitioning toward PD-1

Indexed as

CD4-Positive T-LymphocytesCD57 AntigensCell CommunicationCell DifferentiationCell LineageChemokinesGerminal CenterHumansImmunological SynapsesLymphocyte ActivationPhenotypeProgrammed Cell Death 1 ReceptorReceptors, Antigen, T-CellT Follicular Helper CellsT-Lymphocyte SubsetsCD57 AntigensChemokinesPDCD1 protein, humanProgrammed Cell Death 1 ReceptorReceptors, Antigen, T-Cellimmunological synapseTCR microclustersTFH cell heterogeneity

Identifiers

PMID33903232
PMCPMC8106351

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.